Clarithromycin resistance is reducing the effectiveness of standard regimens for Helicobacter pylori eradication. In the Republic of Korea, a triple regimen of a proton pump inhibitor (PPI), amoxicillin, and metronidazole (PAM) has been used to treat clarithromycin-resistant H. pylori, but decreasing eradication rates prompted evaluation of alternative strategies. This multicenter randomized controlled trial compared PAM, PAM combined with a bismuth compound (PAM-B), and a bismuth-containing quadruple regimen of PPI, bismuth, metronidazole, and tetracycline (PBMT) to test whether PAM-B could improve eradication rates.
This was a prospective multicenter study conducted in Busan and Gyeongsangnam-do, Republic of Korea, enrolling patients with clarithromycin-resistant H. pylori between December 2022 and February 2024. The trial randomized participants to one of three 14-day treatment arms. The abstract reports intention-to-treat (ITT) and per-protocol (PP) analyses of eradication rates and records adverse events; the full text would be required for additional details such as sample size, randomization method, inclusion/exclusion criteria, and baseline demographics, which were not provided in the abstract.
The three 14-day regimens compared were:
Specific drugs, doses, and schedules were not detailed in the abstract and would require the full article for confirmation.
The primary outcome reported in the abstract was H. pylori eradication rate analyzed by ITT and PP populations. Secondary outcomes included the incidence and severity of adverse events, with particular attention to nausea and vomiting. Statistical comparisons between groups are reported as p-values in the abstract.
In the ITT analysis, eradication rates were reported as follows:
The ITT results indicate that adding bismuth to PAM (PAM-B) significantly increased eradication rates compared with PAM alone. Eradication with PAM-B and PBMT did not differ significantly by ITT analysis (p = 0.640).
Per-protocol analyses showed higher overall eradication rates and similar comparative patterns:
In PP analysis, both bismuth-containing regimens (PAM-B and PBMT) produced substantially higher eradication rates than PAM, and eradication rates for PAM-B and PBMT were comparable (p = 0.633).
Adverse events were generally uncommon and reversible. The abstract highlights a specific tolerability advantage with PAM-B: nausea and vomiting were significantly less frequent with PAM-B than with PBMT (6.8% vs 25.0%; p = 0.007). Severe adverse events were reported as rare, and all symptoms resolved after treatment discontinuation. The abstract does not provide a full breakdown of other adverse events, rates of treatment discontinuation, or serious adverse event counts; these details would require the full text.
The investigators conclude that adding bismuth to a PPI–amoxicillin–metronidazole backbone (PAM-B) increased eradication rates compared with PAM and achieved rates comparable to the established bismuth quadruple regimen PBMT, without a significant increase in adverse events. Based on these results, PAM-B is proposed as a potential first-line option for clarithromycin-resistant H. pylori infection. The authors recommend further large-scale studies to validate these findings before broad implementation.
The trial was registered retrospectively with the Clinical Research Information Service (CRIS; KCT0012265). The abstract does not report several important trial details, including total enrollment numbers, exact regimen dosing, randomization procedures, participant baseline characteristics, or a complete adverse event table; these items must be obtained from the full published article to fully assess internal validity and generalizability.
Overall, the abstract reports that a 14-day bismuth-containing PAM (PAM-B) regimen improved eradication rates over PAM and matched the effectiveness of PBMT while appearing better tolerated than PBMT for nausea and vomiting. Further confirmation in larger, fully reported trials was advised by the authors.